Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 24

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 24
---
 stronger growth trajectory.

Merger Agreement with DiamiR

Pursuant to the Letter of
Intent, we entered into the Merger Agreement with DiamiR on July 14, 2025 for the DiamiR Merger. Pursuant to the Merger Agreement, the
Company will newly incorporate a wholly owned, direct subsidiary in the state of Delaware for purposes of consummating the transactions
contemplated therein (the “Merger Sub”). At the closing, subject to terms and conditions of the Merger Agreement, the Merger
Sub will merge with and into DiamiR, with DiamiR surviving, resulting in DiamiR becoming a direct wholly-owned subsidiary of the Company.

Prior to the closing of DiamiR
Merger, the Company will transfer by way of continuation to and domesticate as a Delaware corporation (the “Domestication”;
the Company immediately following the Domestication and prior to the closing of DiamiR Merger, “Aptorum Delaware”). In connection
with the Domestication, each then issued and outstanding Class A ordinary share of the Company will convert automatically, on a one-for-one
basis, into a share of common stock of Aptorum Delaware, each then issued and outstanding Class B ordinary share of the Company will convert
automatically, on a one-for-one basis, into a share of common stock of Aptorum Delaware and a share of non-voting and non-convertible
Series A preferred stock of Aptorum Delaware.

<div align='center'>6</div>

At the closing of DiamiR Merger,
in exchange for all the outstanding common stock of DiamiR, Aptorum Delaware will issue shares of its common stock to stockholders of
DiamiR (excluding the dissenting stockholders to DiamiR Merger), at a pre-determined conversion ratio to the extent that the stockholders
of DiamiR and existing Company shareholders will own approximately 70% and 30%, respectively, of the outstanding shares of the Combined
Company immediately following the closing.

Concurrently with the execution
of the Merger Agreement, ATL, a wholly owned subsidiary of the Company, and DiamiR entered into a management services agreement pursuant
to which ATL shall pay a monthly service fee and reimburse expenses to DiamiR in exchange for the officers and employees of DiamiR providing
services to ATL to develop a diagnostic test for early detection and monitoring of progression of glioblastoma until the earlier of the
closing of the Merger